These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 25486910)

  • 1. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
    Lin SH; Wang J; Saintigny P; Wu CC; Giri U; Zhang J; Menju T; Diao L; Byers L; Weinstein JN; Coombes KR; Girard L; Komaki R; Wistuba II; Date H; Minna JD; Heymach JV
    BMC Genomics; 2014 Dec; 15(1):1079. PubMed ID: 25486910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
    Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
    Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
    Walter K; Holcomb T; Januario T; Du P; Evangelista M; Kartha N; Iniguez L; Soriano R; Huw L; Stern H; Modrusan Z; Seshagiri S; Hampton GM; Amler LC; Bourgon R; Yauch RL; Shames DS
    Clin Cancer Res; 2012 Apr; 18(8):2360-73. PubMed ID: 22261801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
    Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
    Wu X
    Gene; 2018 Feb; 643():74-82. PubMed ID: 29221754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
    Maeda M; Murakami Y; Watari K; Kuwano M; Izumi H; Ono M
    Lung Cancer; 2015 Mar; 87(3):265-71. PubMed ID: 25638724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC.
    Horie M; Kaczkowski B; Ohshima M; Matsuzaki H; Noguchi S; Mikami Y; Lizio M; Itoh M; Kawaji H; Lassmann T; Carninci P; Hayashizaki Y; Forrest ARR; Takai D; Yamaguchi Y; Micke P; Saito A; Nagase T
    Mol Cancer Res; 2017 Oct; 15(10):1354-1365. PubMed ID: 28698358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase Cα mediates erlotinib resistance in lung cancer cells.
    Abera MB; Kazanietz MG
    Mol Pharmacol; 2015 May; 87(5):832-41. PubMed ID: 25724832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in non-small cell lung cancer that drives the EMT phenotype.
    Zhang L; Zhang J; Ma Y; Chen J; Dong B; Zhao W; Wang X; Zheng Q; Fang F; Yang Y
    Lung Cancer; 2015 Sep; 89(3):320-8. PubMed ID: 26144287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
    Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
    Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
    Virmani AK; Tsou JA; Siegmund KD; Shen LY; Long TI; Laird PW; Gazdar AF; Laird-Offringa IA
    Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):291-7. PubMed ID: 11895880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic down-regulation of death-associated protein kinase in lung cancers.
    Toyooka S; Toyooka KO; Miyajima K; Reddy JL; Toyota M; Sathyanarayana UG; Padar A; Tockman MS; Lam S; Shivapurkar N; Gazdar AF
    Clin Cancer Res; 2003 Aug; 9(8):3034-41. PubMed ID: 12912953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China.
    Wang J; Duan Y; Meng QH; Gong R; Guo C; Zhao Y; Zhang Y
    PLoS One; 2018; 13(10):e0203155. PubMed ID: 30286088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
    Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
    PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
    Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
    Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.